Using AI to create personalized treatments for Alzheimer's Disease
Official title: SmartAD for Intelligent Alzheimer’s Disease(AD) Personalized Combination Therapy
Funded at University of Pittsburgh at Pittsburgh · NIH-10701069 · Data updated 2026-11-12
This study is working on a smart app that will help doctors create personalized treatment plans for people with Alzheimer's Disease who also have other health issues like heart problems, diabetes, or depression, by looking at how different medications affect their thinking skills.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | September 15, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $395,417 |
| NIH project number | 5R56AG074951-02 |
| Project ID | NIH-10701069 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are Alzheimer's Disease patients who also have comorbid conditions such as cardiovascular diseases, diabetes, or depression.
✕Less likely to help
Patients with Alzheimer's Disease who do not have any comorbidities may not benefit from this research.
What this research studies
This research aims to develop an artificial intelligence application called SmartAD that will help evaluate cognitive functions and create personalized treatment plans for Alzheimer's Disease (AD) patients who also have common comorbidities like cardiovascular diseases, diabetes, and depression. By analyzing clinical data from the University of Pittsburgh Alzheimer’s Disease Research Center, the project seeks to understand how different medications for these comorbidities can impact cognitive functions in AD patients. The goal is to improve treatment outcomes by tailoring therapies based on individual patient profiles and their specific health conditions.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for Alzheimer's Disease patients, potentially improving their cognitive function and quality of life.
How similar studies have gone: While the use of AI in healthcare is gaining traction, this specific approach to combining comorbidity medications for Alzheimer's Disease is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Xie, Xiang-Qun — University of Pittsburgh at Pittsburgh
- Study coordinator: Xie, Xiang-Qun
Related research
Other NIH-funded projects on the same topics.
-
Alzheimer’s disease and related brain changes linked to chemicals in the body
This NIH grant supports a patient-centered effort to map how environmental exposures and body chemistry relate to Alzheimer’s disease and related dementias.
-
Understanding how everyday exposures affect Alzheimer's disease progression
A national research effort is studying how environmental exposures, gut health, diet, and metabolism relate to Alzheimer's and related dementias to identify new ways to diagnose and treat these conditions.
-
How environment, gut health, and metabolism affect Alzheimer’s disease
This grant looks at how environmental exposures, gut microbes, diet, and metabolism influence Alzheimer’s disease and related dementias.
-
Understanding how chemical exposures affect Alzheimer's disease progression
This project studies how environmental chemicals and other biological factors influence brain health and the course of Alzheimer’s disease and related dementias.
-
Understanding how brain hyperexcitability and sex differences affect Alzheimer’s disease
This grant tests whether brain hyperexcitability linked to a genetic risk (APOE4) and sex differences contribute to memory decline in Alzheimer’s disease, using computer simulations and mouse data to guide potential human treatments.
-
CNS Exosomes and Adaptive Immunity in Alzheimer’s Disease
This project studies how tiny brain vesicles called exosomes may activate the body's immune system in Alzheimer’s disease, with the goal of understanding mechanisms that could lead to new treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.